Merck: Better Times Ahead On Approvals And Outlook
After a forgettable last year, Merck & Co., Inc.'s stock price is up 20% YTD, supported by approvals, a positive outlook for 2024, and an attractive forward P/E. Keytruda, the company's top-selling...
After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
Given its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs.
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck (MRK) Rises Higher Than Market: Key Facts
Merck (MRK) reachead $131.95 at the closing of the latest trading day, reflecting a +0.15% change compared to its last close.
Three-Stock Lunch: Tesla, Merck, and RH
Jerry Castellini, Castle Ark Management president and CIO, joins 'Power Lunch' to discuss Castellini's investing take on three stocks: Tesla, Merck, and RH.
Merck shares move higher as lung disorder drug secures ‘squeaky clean' label from FDA
Merck & Co Inc (NYSE:MRK, ETR:6MK) shares traded more than 4% higher after it won US Food and Drug Administration (FDA) approval for its lung disorder drug sotatercept, brand name WINREVAIR. After...
Merck Stock Nabs Record High After FDA Approval
Merck & Co Inc (NYSE:MRK) was last seen up 4.4% to trade at $130.99, after the Food and Drug Administration (FDA) approved its Winrevair treatment for adults with high blood pressure due to constr...
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.
Merck shares rise on FDA approval for Winrevair
Merck shares gain 5% to $131.90 in afterhours trading following approval of its new drug for a potentially fatal lung disease.
FDA approves Merck's drug for rare, deadly lung condition
The approval is a win for Merck, which is working to diversify its revenue stream as its blockbuster cancer drug Keytruda nears a loss of market exclusivity.
US FDA approves Merck's blood pressure therapy
The U.S. FDA on Tuesday approved Merck's treatment for adults with high blood pressure due to constriction of lung arteries, adding another potential blockbuster drug to the pharmaceutical giant's ...
Merck's $11.5 Billion Bet on Its Next Big Drug Finally Arrives
The newly approved drug, which treats potentially fatal pulmonary arterial hypertension, is estimated to ring up as much as $7.5 billion in yearly sales.
Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study
Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.
Merck's cervical cancer therapy met main goal in late-stage study
Merck said on Friday its drug Keytruda, in combination with chemoradiotherapy, met the main goal in a late-stage study in newly diagnosed patients with high-risk locally advanced cervical cancer.
Here's Why Merck (MRK) Fell More Than Broader Market
Merck (MRK) concluded the recent trading session at $122.16, signifying a -0.41% move from its prior day's close.
Related Companies